首页> 外文期刊>Journal of Agricultural and Food Chemistry >Plasma and Tissue Depletion of Florfenicol and Florfenicol-amine in Chickens
【24h】

Plasma and Tissue Depletion of Florfenicol and Florfenicol-amine in Chickens

机译:鸡体内氟苯尼考和氟苯尼考胺的血浆和组织消耗

获取原文
获取原文并翻译 | 示例
           

摘要

Chickens were used to investigate plasma disposition of florfenicol after single intravenous (i.v.) and oral dose (20 mg kg~(-1) body weight) and to study residue depletion of florfenicol and its major metabolite florfenicol-amine after multiple oral doses (40 mg kg~(-1) body weight, daily for 3 days). Plasma and tissue samples were analyzed using a high-performance liquid chromatography (HPLC) method. After i.v. and oral administration, plasma concentration-time curves were best described by a two-compartment open model. The mean [±standard deviation (SD)] elimination half-life (t~1/2β) of florfenicol in plasma was 7.90 ± 0.48 and 8.34 ± 0.64 h after i.v. and oral administration, respectively. The maximum plasma concentration was 10.23 ± 1.67 μg mL~(-1), and the interval from oral administration until maximal concentration was 0.63 ± 0.07 h. Oral bioavailability was found to be 87 ± 16%. Florfenicol was converted to florfenicol-amine. After multiple oral dose (40 mg kg~(-1) body weight, daily for 3 days), in kidney and liver, concentrations of florfenicol (119.34 ± 31.81 and 817.34 ± 91.65 μg kg~(-1), respectively) and florfenicol-amine (60.67 ± 13.05 and 48.50 ± 13.07 μg kg~(-1), respectively) persisted for 7 days. The prolonged presence of residues of florfenicol and florfenicol-amine in edible tissues can play an important role in human food safety, because the compounds could give rise to a possible health risk. A withdrawal time of 6 days was necessary to ensure that the residues of florfenicol were less than the maximal residue limits or tolerance established by the European Union.
机译:鸡用于研究单次静脉内(iv)和口服剂量(20 mg kg〜(-1)体重)后氟苯尼考的​​血浆处置,并研究多次口服剂量后氟苯尼考及其主要代谢物氟苯尼考胺的残留量(40 mg kg〜(-1)体重,每天3天。使用高效液相色谱(HPLC)方法分析血浆和组织样品。在i.v.之后和口服给药,血浆浓度-时间曲线最好用两室开放模型描述。静脉注射后氟苯尼考在血浆中的平均[±标准偏差(SD)]消除半衰期(t〜1 /2β)为7.90±0.48和8.34±0.64 h。和口服给药。最高血浆浓度为10.23±1.67μgmL〜(-1),从口服到最大浓度的时间间隔为0.63±0.07 h。口服生物利用度为87±16%。将氟苯尼考转化为氟苯尼考胺。多次口服(体重40 mg kg〜(-1),每天3天)后,在肾脏和肝脏中氟苯尼考的​​浓度(分别为119.34±31.81和817.34±91.65μgkg〜(-1))和氟苯尼考的​​浓度-胺(分别为60.67±13.05和48.50±13.07μgkg〜(-1))持续7天。可食用组织中氟苯尼考和氟苯尼考胺残留的长期存在可能对人类食品安全起重要作用,因为这些化合物可能引起健康风险。为确保氟苯尼考的​​残留量小于欧盟规定的最大残留限量或耐受性,必须停药6天。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号